EAACI Congress 2024
BackBiologicals 1
Friday 31 May, 12:00 PM -
13:00 PM Valencia, Spain
Poster Zone
Thematic Poster Session
12:00
12 months retrospective real-life study on the clinical course of CRSwNP and respiratory function in patients with EGPA treated with biological drugs
12:00
A Case of EGPA Treated with Mepolizumab
12:00
Baseline Characteristics of Patients with Severe Asthma in Spain according to biological treatment use: BREATHE study
12:00
Baseline disease burden in severe asthma patients treated with biologics, and eligible but not treated: Spanish patients in the ISAR Registry
12:00
Budget impact of omalizumab biosimilar from the French healthcare perspective
12:00
Efficacy and injection schedule adjustment of Dupilumab in patients with chronic rhinosinusitis: Recent experiences in SNUH
12:00
Eosinophilia over dupilumab treatment in asthma patients: a multicentric retrospective study
12:00
Evaluation of Early Real-World Efficacy and Safety of Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis Through a Multidisciplinary Approach
12:00
Flow cytometry analysis of peripheral blood CRTH2+ cell subpopulations of dupilumab-treated patients
12:00
Longitudinal Assessment of Dupilumab's Therapeutic Effects in Chronic Rhinosinusitis with Nasal Polyps
12:00
MY010: anti-allergen antibodies for the treatment of Fagales pollen allergy
12:00
Mepolizumab Efficacy in Eosinophilic Granulomatosis with Polyangiitis with intractable middle ear effusion: a Case Report
12:00
Real-Life Effectiveness of Mepolizumab and Omalizumab in Sever Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study
